Mounjaro®
Starting from £179.99/mo
Start journey Learn moreFeeling no appetite at all on Wegovy is one of the most commonly reported experiences during the first weeks of treatment. Semaglutide works directly on GLP-1 receptors in the brain's appetite-regulation centres, and for some people the effect is striking enough that eating feels almost entirely unnecessary. That is not a malfunction. Clinical trial data published in the STEP 1 study in the New England Journal of Medicine showed semaglutide produced substantially reduced hunger scores compared with placebo across 68 weeks — the appetite reduction is the mechanism working. What matters clinically is how you respond to it. These are prescription-only medicines, and how to manage appetite changes safely is something a prescriber or clinical pharmacist should guide you through personally.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 trial was not only a weight-loss study. Participants completed validated hunger and appetite questionnaires throughout, and semaglutide consistently produced greater reductions in hunger, cravings and prospective food consumption than placebo. The effect was not subtle in many participants. Some reported that entire days passed without any meaningful sense of hunger. The NHS medicines page for semaglutide lists reduced appetite as an expected effect, not a side effect to be stopped.
Gastric emptying slows significantly on semaglutide. Food stays in the stomach longer, which sustains satiety signals well beyond a normal meal. GLP-1 receptors in the hypothalamus also receive direct signals that reduce the drive to eat. These two pathways reinforce each other. At higher doses, both effects intensify, which is why a transition to 1.7mg or 2.4mg often brings the sharpest drop in appetite. The practical upshot is that at maintenance dose, some people do not feel hungry at all for hours, sometimes most of the day.
This is the pharmacology working, and our page on Wegovy loss of appetite explains in detail why this suppression happens and what to expect across the dose stages. Concern is only warranted when it tips into an inability to maintain any meaningful nutrition, a distinction our clinical team can help you draw.
Appetite suppression is the goal. Eating almost nothing is a different problem. When calorie intake drops sharply without attention to what those calories contain, the body draws on both fat and lean muscle mass. Muscle loss is harder to reverse than fat gain, and it undermines the long-term metabolic benefit that makes Wegovy worth taking in the first place.
There is a quick habit worth building into your day: before your first meal, check whether it contains a meaningful source of protein, chicken, fish, eggs, Greek yoghurt, legumes, tofu. If it does not, adjust before you eat rather than after. That single minute of checking, done consistently, does more for body composition than any supplement. The British Dietetic Association's food facts guidance is a practical free resource for building this kind of thinking into low-appetite eating.
Aim for adequate hydration too. Nausea and reduced thirst can compound each other on semaglutide, and mild dehydration makes fatigue and light-headedness worse. Small, frequent, protein-forward meals tend to work better than waiting for hunger to arrive and then eating a full plate. For more detailed guidance on building meals around treatment, our Wegovy eating guide covers this in full.
Most total appetite loss on Wegovy is transient and dose-linked. It typically peaks in the first one to two weeks after a dose step and then softens. If it does not soften, or if it is accompanied by persistent nausea, vomiting, or an inability to keep fluids down, that picture needs clinical review.
There are two specific warning signs that should prompt same-day contact with your prescriber. First, severe or persistent abdominal pain that radiates toward the back, the MHRA highlighted acute pancreatitis as a known but infrequent serious risk for GLP-1 medicines in a Drug Safety Update issued in January 2026, and this symptom pattern should never be waited out. Second, signs of dehydration from prolonged vomiting or diarrhoea, these can affect kidney function and need prompt assessment.
If your appetite has simply vanished but you feel well, you are keeping fluid down, and you can manage small structured meals, you are likely in the expected adjustment window. Understanding what drives appetite loss on Wegovy in more detail can help you distinguish the normal from the notable. If you are unsure which category you are in, that uncertainty itself is a reason to reach out, not to search forums.
Waiting to feel hungry on Wegovy often means not eating. Scheduled eating works better. Three small meals at fixed times, regardless of appetite, gives you a framework to meet nutritional minimums without relying on a cue that may not arrive. Each one does not need to be large. A hundred grams of cottage cheese with some fruit, a small portion of salmon with vegetables, two eggs with a slice of wholegrain bread: these are nutritionally meaningful even when they feel like more than you want.
Liquid nutrition can fill gaps. A protein-rich smoothie or a fortified soup is easier to manage than solid food when gastric emptying is significantly slowed. Alcohol is worth avoiding; it adds calories without nutrition and interacts poorly with the nausea that often accompanies appetite suppression.
The appetite picture often changes across a treatment course. People who experience near-total appetite loss at 1.7mg sometimes find it moderates at 2.4mg, or stabilises after a few weeks at any given dose. Tracking what you eat (even roughly) helps you and your prescriber see whether intake is genuinely adequate. There is more on the broader relationship between semaglutide and appetite if you want to understand the mechanism further, and our Wegovy overview covers the full clinical picture from eligibility through to results. For questions about how treatment costs fit into the picture, Wegovy pricing in the UK lays out what a private prescription typically includes.
If you are finding the appetite change difficult to manage, or you are uncertain whether what you are experiencing is within the expected range, our prescribers are available seven days a week. Speak to our prescribers through a free consultation and get a clinical view on your specific situation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.